Overview
- Disruption of cell cycle control and apoptosis is a near-universal feature of human malignancy.
- The molecular machinery involved, the cyclin-CDK engine, RB1 and TP53 checkpoint systems, the BCL-2 family apoptotic rheostat, the caspase execution cascade, and the MDM2 regulatory axis, directly determines tumour grade and behaviour and underlies most clinically relevant drug resistance mechanisms.
- These concepts are foundational to adrenal neoplasm pathology and the RCPA Fellowship examination.
The CDK/Cyclin Engine
Core Complexes
- CDKs are constitutively expressed serine/threonine kinases that are catalytically inactive alone.
- Binding to transiently synthesised cyclins confers oscillatory kinase activity.
- More than 15 cyclins have been identified; cyclins D, E, A, and B appear sequentially and bind one or more CDKs.
| Phase Transition | Active Complex(es) | Key Substrate |
|---|---|---|
| $G_1 \rightarrow S$ | Cyclin D-CDK4, Cyclin D-CDK6 | RB |
| Late $G_1 \rightarrow S$ | Cyclin E-CDK2 | RB; replication factors |
| $S$ phase | Cyclin A-CDK2 | DNA replication machinery |
| $G_2 \rightarrow M$ | Cyclin A-CDK1, Cyclin B-CDK1 | Mitotic apparatus |
The restriction point in $G_1$ is the critical commitment gate beyond which cells complete division regardless of mitogenic signals.
CDK Inhibitors (CDKIs)
Two structurally and functionally distinct families exert negative control:
| Family | Members | Targets | Key Inducers |
|---|---|---|---|
| INK4 | p15 (CDKN2B), p16 (CDKN2A), p18 (CDKN2C), p19 (CDKN2D) | Cyclin D-CDK4 and Cyclin D-CDK6 (selective) | TGF-β; oncogene-induced senescence |
| CIP/KIP | p21 (CDKN1A), p27 (CDKN1B), p57 (CDKN1C) | All CDK-cyclin complexes (broad) | p53 (p21); TGF-β (p27) |
- Loss of CDKI function, most commonly homozygous deletion or promoter hypermethylation of CDKN2A, is among the most frequent molecular events across solid tumours.
- Defective CDKIs permit division of cells with damaged DNA, generating mutated daughter cells at risk of malignant transformation.
RB1: Governor of the G₁/S Checkpoint
Mechanism
- RB1 encodes a pocket protein that, in its hypophosphorylated (active) state, binds and sequesters E2F transcription factors.
- The RB-E2F complex recruits histone deacetylases and histone methyltransferases to repress transcription of S-phase genes.
- Sequential phosphorylation by Cyclin D-CDK4/6 and then Cyclin E-CDK2 hyperphosphorylates RB, releasing E2F to activate S-phase gene transcription.
- Once past the restriction point, cells are committed to completing mitosis.
Mechanisms of RB Inactivation in Cancer
The G₁/S checkpoint is defective in most cancers through mutation of one of four regulatory nodes:
| Mechanism | Prototypic Cancer(s) |
|---|---|
| Biallelic loss-of-function RB1 mutation | Retinoblastoma, osteosarcoma, small cell lung carcinoma |
| CDK4 gene amplification | Melanoma, sarcoma, glioblastoma |
| Cyclin D gene amplification (D1, D2, D3) or translocation | Breast carcinoma; lymphoid tumours |
| CDKN2A (p16/INK4a) loss-of-function | Pancreatic carcinoma, melanoma |
| HPV E7 oncoprotein binding to hypophosphorylated RB | Cervical carcinoma |
Downstream consequence: Aberrant E2F liberation drives constitutive S-phase transcription. Beyond dysregulated proliferation, this checkpoint failure impairs DNA damage surveillance, fostering genomic instability and a mutator phenotype.
TP53: Guardian of the Genome
Activation
- TP53 (17p13.1) encodes a tetrameric transcription factor, the central cellular stress monitor.
- Under basal conditions, MDM2 continuously ubiquitinates p53, targeting it for proteasomal degradation.
- Stress disrupts this interaction, stabilising p53.
Two principal activation checkpoints:
- DNA damage checkpoint: ATM/ATR kinases → Chk1/Chk2 → phosphorylation of both p53 and MDM2 → dissociation → p53 accumulation
- Oncogene checkpoint: Oncoproteins (e.g. MYC, RAS) → aberrant G₁/S signalling → p14/ARF upregulation → MDM2 sequestration → p53 stabilisation
Additional inducers: hypoxia, ribonucleotide depletion, telomere shortening.
p53 Effector Programmes
| Programme | Key Mediators | Circumstances |
|---|---|---|
| Transient $G_1$ arrest | p21 (CDKN1A) → CDK inhibition | Mild, repairable damage |
| Permanent senescence | p21, p16, chromatin remodelling | Moderate persistent stress; oncogene activation |
| Apoptosis | BAX, PUMA, NOXA upregulation | Severe irreparable damage |
| Metabolic reprogramming | Inhibition of anabolic pathways | Supports arrest/senescence programmes |
MDM2 Regulation
MDM2 operates via classic negative feedback:
- p53 transcriptionally activates MDM2
- MDM2 binds the p53 N-terminal transactivation domain → inhibits transcriptional activity and targets p53 for ubiquitin-mediated proteasomal degradation
- ATM-mediated phosphorylation of both proteins under genotoxic stress disrupts this interaction
- p14/ARF (encoded by an alternative reading frame of CDKN2A, distinct from p16/INK4a) binds and sequesters MDM2, preventing p53 degradation.
- This is the principal mechanism by which oncogenic signalling engages the p53 pathway, the oncogene checkpoint.
Cancer-associated disruption of the MDM2-p53 axis:
| Mechanism | Consequence |
|---|---|
| Biallelic TP53 loss-of-function mutation (>50% of all cancers) | Abolishes all p53-dependent arrest, senescence, and apoptosis |
| MDM2 gene amplification | Excessive p53 degradation despite wild-type TP53; paradigmatic in WD/DD liposarcoma |
| CDKN2A deletion (loss of p14/ARF) | MDM2 not sequestered; p53 functionally impaired |
| HPV E6 oncoprotein | Ubiquitinates and degrades p53 (cervical carcinoma) |
| Li-Fraumeni syndrome | Germline TP53 mutation; heterozygous carriers develop wide spectrum of cancers |
BCL-2 Family: The Apoptotic Rheostat
Intrinsic (Mitochondrial) Pathway
- The intrinsic pathway is governed by BCL-2 family proteins controlling mitochondrial outer membrane permeabilisation (MOMP).
- Once MOMP occurs, cytochrome c is released, binds APAF-1 to form the apoptosome, and activates caspase-9.
| Subgroup | Members | Function | BH Domains |
|---|---|---|---|
| Anti-apoptotic | BCL-2, BCL-XL, MCL-1, BCL-W, A1 | Inhibit MOMP; sequester pro-apoptotic proteins | BH1-4 |
| Pro-apoptotic effectors | BAX, BAK | Oligomerise to form mitochondrial membrane pores | BH1-3 |
| BH3-only (sensitisers/activators) | BIM, PUMA, NOXA, BAD, BID, HRK | Activate BAX/BAK directly or neutralise anti-apoptotic members | BH3 only |
- The balance between these subgroups determines cell fate. p53 upregulates PUMA and NOXA, tipping balance toward apoptosis.
- Loss of p53 function specifically prevents PUMA upregulation in response to DNA damage, enabling survival of cells that would otherwise undergo apoptosis.
IAPs (Inhibitor of Apoptosis Proteins) provide an additional brake by blocking active caspase-9; SMAC/DIABLO, co-released from mitochondria with cytochrome c, neutralises IAPs.
- Prototypic example: Follicular lymphoma, $t(14;18)(q32;q21)$ fuses BCL2 to the immunoglobulin heavy-chain locus, driving constitutive BCL-2 overexpression.
- Indolent behaviour reflects reduced cell death rather than explosive proliferation.
Extrinsic (Death Receptor) Pathway
- Ligand binding to FAS/CD95 or TNFR1 → receptor clustering → FADD recruitment → caspase-8 activation (initiator).
- Caspase-8 directly activates executioner caspases or cleaves BID to truncated BID (tBID), which amplifies the signal via the intrinsic pathway (cross-talk).
- FLIP (competes with caspase-8 for FADD) is an intracellular inhibitor expressed by normal but not tumour cells that confers selectivity to TRAIL-based approaches.
Caspase Cascade: The Execution Phase
Caspases (cysteine-aspartate proteases) exist as inactive zymogens activated by proteolytic cleavage:
$$\text{Procaspase} \xrightarrow{\text{proteolytic cleavage}} \text{Active caspase}$$
| Class | Key Members | Activating Signal |
|---|---|---|
| Initiator | Caspase-8, Caspase-9 | Death receptor (extrinsic); apoptosome (intrinsic) |
| Executioner | Caspase-3, Caspase-6, Caspase-7 | Cleavage by initiator caspases |
- Executioner caspases cleave structural proteins (lamins, cytoskeletal components), DNA repair enzymes, and CAD/ICAD (releasing the DNase responsible for internucleosomal DNA laddering).
- Morphological hallmarks: nuclear condensation (pyknosis), nuclear fragmentation (karyorrhexis), cell shrinkage, intact membrane blebbing into apoptotic bodies, no inflammatory response.
Cancer cells evade apoptosis via:
- Loss of TP53 function → failure to upregulate PUMA/BAX
- Overexpression of anti-apoptotic BCL-2 family members (BCL-2, MCL-1)
- Epigenetic silencing of APAF-1 or caspase-8
- Overexpression of IAPs
Implications for Tumour Grade and Drug Resistance
Tumour Grade
Higher-grade tumours characteristically show:
- Elevated Ki-67 proliferative index (dysregulated CDK/cyclin activity):
$$\text{Ki-67 index} = \frac{\text{Ki-67 positive nuclei}}{\text{total nuclei counted}} \times 100\%$$
- TP53 loss (genomic instability, pleomorphism, high mitotic rate)
- RB1 loss (unrestrained S-phase entry)
- Reduced apoptosis (BCL-2 overexpression, caspase pathway silencing)
- In adrenocortical carcinoma, the Weiss scoring system assigns points for high mitotic rate (>5/50 HPF) and atypical mitoses, both direct reflections of deranged CDK/cyclin and checkpoint function.
- High-grade ACC frequently demonstrates TP53 mutation and CDKN2A loss.
Drug Resistance
| Mechanism | Molecular Basis |
|---|---|
| Resistance to genotoxic chemotherapy/radiotherapy | TP53 mutation prevents apoptosis induction; TP53 mutation frequency is higher at relapse than diagnosis |
| BCL-2/MCL-1 overexpression | Buffers BH3-only protein induction by chemotherapy-induced stress |
| MDM2 amplification | Blocks p53-mediated apoptotic response to DNA damage despite wild-type TP53 |
| Multidrug resistance (MDR) | ABC transporter overexpression (P-glycoprotein/PGP); ATP-dependent efflux of chemotherapeutic agents |
| APAF-1 or caspase-8 epigenetic silencing | Direct blockade of apoptosome formation or extrinsic pathway execution |
| CDK4 amplification | Overrides G₁ checkpoint; sustains proliferation despite DNA damage |
| PI3K/AKT pathway activation | Promotes tumour cell survival; downstream target of multiple oncogenic signals |
Therapeutic Exploitation
| Agent Class | Example | Target | Approved Indication |
|---|---|---|---|
| CDK4/6 inhibitors | Palbociclib, ribociclib, abemaciclib | CDK4/6 → restore RB-mediated G₁ arrest | HR+/HER2− advanced breast carcinoma |
| BH3 mimetics | Venetoclax | BCL-2 hydrophobic groove; displaces BH3-only proteins | CLL with 17p deletion; AML |
| MDM2 inhibitors | Under investigation | MDM2-p53 interaction; reactivate wild-type p53 | MDM2-amplified tumours (e.g. WD/DD liposarcoma) |
Diagnostic Pitfalls
- p53 IHC interpretation: Both complete absence of staining (nonsense/frameshift → unstable protein) and diffuse strong overexpression (missense → stabilised non-functional protein) indicate TP53 loss-of-function. Wild-type p53 produces heterogeneous low-level staining. Diffuse strong positivity must not be interpreted as functional p53.
- BCL-2 in follicular lymphoma vs reactive germinal centres: Reactive germinal-centre B-cells are BCL-2 negative; follicular lymphoma cells are BCL-2 positive, a key diagnostic distinction.
- MDM2 amplification without TP53 mutation: WD/DD liposarcoma is the paradigmatic example, high-level MDM2 amplification at 12q13-15 effectively silences wild-type p53; MDM2 IHC and FISH are key ancillary tests.
- CDKN2A locus duality: A single locus encodes both p16/INK4a (CDK4/6 inhibitor → RB pathway) and p14/ARF (MDM2 inhibitor → p53 pathway) via alternative reading frames; deletion simultaneously disables both tumour suppressor axes.
- Ki-67 quantification: Intratumoral heterogeneity and fixation artefacts affect results; standardised hot-spot methodology per RCPA/WHO guidelines is required for reproducible grading.